Treatment of Exudative Age-related Macular Degeneration – Data from the Daily Clinical Practice in European Countries

Wydanie 2/2018
str. 31 – 35

Autor: Małgorzata Figurska

Klinika Okulistyki Wojskowego Instytutu Medycznego, Centralny Szpital Kliniczny Ministerstwa Obrony Narodowej w Warszawie
Kierownik: prof. dr hab. n. med. Marek Rękas

Summary: Clinical trials (VIEW, MARINA, ANCHOR) of antiangiogenic drugs have demonstrated very good functional and morphological results in neovascular (wet) form of age-related macular degeneration treatment under strict adherence and/ or intensive intravitreal dosing regimen.

Clinical trials with less restrictive monitoring or less frequent dosing regimen (PIER, SAILOR) have shown significantly weaker therapeutic effects, even with the initial loading phase. It should, however, be borne in mind that strictly defined inclusion criteria in clinical trials do not necessarily reflect daily clinical practice conditions. The article discusses the efficacy of wet age-related macular degeneration treatment with ranibizumab and aflibercept based on electronic medical records and European experiences (LUMINOUS, AURA, PERSEUS).